Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the…
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing --…